UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: June 30, 1999
Check here if Amendment: |_|; Amendment Number: ____
This Amendment (Check only one): |_| is a restatement.
|_| adds new holdings
entries.
Institutional Investmtne Manager Filing this Report:
Name: OrbiMed Advisers Inc.
Address: 757 Third Avenue, 6th Floor
New York, NY 10010
Form 13F File Number: 28-6776
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables, are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Samuel D. Isaly
Title: President
Phone: (212) 739-6400
Signature, Place, and Date of Signing:
/s/ Samuel D. Isaly New York, NY August 13, 1999
- --------------------- ---------------------- ---------------------
[Signature] [City, State] [Date]
Report Type (Check one only):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
<PAGE>
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 1
Form 13F Information Table Entry Total: 40
Form 13F Information Table Value Total: $287,315
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file nember(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings
and list entries.]
No. Form 13F File Number Name
2 28-6774 OrbiMed Advisors LLC
<PAGE>
FORM 13F INFORMATION TABLE
Quarter Ended June 30, 1999
Manager Key: (1) OrbiMed Advisers Inc.
(2) OrbiMed Advisors LLC
<TABLE>
<CAPTION>
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
- ------------------------------------------------------------------------------------------------------------------------------------
Investment Discretion Voting Authority (Shares)
- ------------------------------------------------------------------------------------------------------------------------------------
Title of CUSIP Market SHRS Sole Shared Shared Other Sole Shared None
Name of Issuer Class Number Value Defined Other Managers
(x$1000)
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Abgenix, Inc COM 00339B107 6,358,470 319,923 X 1 319,923
Abgenix, Inc COM 00339B107 5,696,473 286,615 X 2 286,615
Alexion Pharmaceuticals, COM 015351109 2,396,250 270,000 X 1 270,000
Inc.
Alexion Pharmaceuticals, COM 015351109 4,264,437 480,500 X 2 480,500
Inc.
Aquila COM 03839f107 849,875 523,000 X 2 523,000
Biopharmaceuticals
Aronex COM 042666206 2,595,937 585,000 X 2 585,000
Aviron COM 053762100 3,593,750 125,000 X 1 125,000
Aviron COM 053762100 9,616,875 334,500 X 2 334,500
Bio-Technology General COM 090578105 2,600,000 400,000 X 1 400,000
Bio-Technology General COM 090578105 3,575,000 550,000 X 2 550,000
CV Therapeutics COM 126667104 2,472,250 449,500 X 2 449,500
Centocor Inc. COM 152342101 10,490,625 225,000 X 1 225,000
Centocor Inc. COM 152342101 21,913,750 470,000 X 2 470,000
Eli Lilly & Company COM 532457108 7,878,750 110,000 X 1 110,000
Eli Lilly & Company COM 532457108 11,639,062 162,500 X 2 162,500
Enzon Inc. COM 293904108 2,937,625 142,000 X 2 142,000
Genzyme Corp. General COM 372917104 7,275,000 150,000 X 1 150,000
Division
Genzyme Corp. General COM 372917104 15,277,500 315,000 X 2 315,000
Division
Gilead Sciences Inc. COM 375558103 8,020,375 153,500 X 1 153,500
Gilead Sciences Inc. COM 375558103 12,670,625 2,425,000 X 2 2,425,000
Hyseq Inc. COM 449163302 1,236,609 356,500 X 2 356,500
Incyte Pharmaceuticals COM 45337c102 2,908,125 110,000 X 1 110,000
Inc.
Incyte Pharmaceuticals COM 45337c102 6,345,000 240,000 X 2 240,000
Inc.
Merck, Inc. COM 589331107 5,521,875 75,000 X 1 75,000
Merck, Inc. COM 589331107 12,258,562 166,500 X 2 166,500
Monsanto COM 611662107 7,912,500 200,000 X 1 200,000
Monsanto COM 611662107 16,181,062 409,000 X 2 409,000
Pharmacia and Upjohn COM 716941109 6,817,500 120,000 X 1 120,000
Inc.
Pharmacia and Upjohn COM 716941109 16,589,250 292,000 X 2 292,000
Inc.
Pharmacopeia Inc. COM 71713B104 3,037,500 270,000 X 1 270,000
Pharmacopeia Inc. COM 71713B104 3,196,125 284,100 X 2 284,100
Premier Research COM 740568100 1,498,125 235,000 X 1 235,000
Worldwide
SangStat Medical Corp. COM 801003104 4,485,000 260,000 X 1 260,000
SangStat Medical Corp. COM 801003104 7,935,000 460,000 X 2 460,000
Titan Pharmaceutical COM 888314101 2,592,187 525,000 X 2 525,000
Triangle Pharmaceutical COM 89589H104 3,600,000 200,000 X 1 200,000
Triangle Pharmaceutical COM 89589H104 2,448,000 136,000 X 2 136,000
Vertex Pharmaceuticals COM 92532F100 5,428,125 225,000 X 1 225,000
Inc.
Vertex Pharmaceuticals COM 92532F100 6,996,250 290,000 X 2 290,000
Inc.
Warner-Lambert Co. COM 934488107 9,774,049 141,269 X 1 141,269
Warner-Lambert Co. COM 934488107 18,431,550 266,400 X 2 266,400
Total 287315023 13738807 13738807
</TABLE>
